Literature DB >> 10418778

The effects of atypical antipsychotics and phencyclidine (PCP) on rotorod performance.

R E Steinpreis1, K A Anders, E M Branda, C K Kruschel.   

Abstract

A series of six experiments were conducted to determine the effects of haloperidol, clozapine, olanzapine, and phencyclidine (PCP) on rotorod performance. Rodents were trained to walk on a rotorod to avoid a mild shock to a criterion of 20 rpm for 3 min. None of the vehicles of any of these drugs disrupted rotorod performance. Haloperidol disrupted rotorod performance at doses of 0.03, 0.1, and 0.3 mg/kg, and olanzapine disrupted rotorod performance at doses of 3.0 and 10.0 mg/kg. Clozapine produced a much milder disruption across all three doses (3.0, 10.0, and 30.0 mg/kg). PCP produced a consistent and severe disruption of rotorod performance at doses of 4.0 and 6.0 mg/kg, but not at a dose of 2.0 mg/kg. Twenty-four hours postinjection there were no residual PCP effects on rotorod performance. Coadministration of either haloperidol or olanzapine with PCP did not reverse PCP-induced disruption in rotorod performance, while clozapine produced a partial reversal at only one dose. These findings indicate that olanzapine functions similarly to classic antipsychotics with respect to their effects on locomotion and balance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10418778     DOI: 10.1016/s0091-3057(99)00010-6

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  6 in total

1.  Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice.

Authors:  Julie A Marusich; Kateland R Grant; Bruce E Blough; Jenny L Wiley
Journal:  Neurotoxicology       Date:  2012-08-23       Impact factor: 4.294

2.  Paw-Print Analysis of Contrast-Enhanced Recordings (PrAnCER): A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits.

Authors:  Hayley A Bounds; Devon L Poeta; Petra M Klinge; Rebecca D Burwell
Journal:  J Vis Exp       Date:  2019-08-12       Impact factor: 1.355

3.  Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia.

Authors:  Caterina P Profaci; Kristyn A Krolikowski; Rafal T Olszewski; Joseph H Neale
Journal:  Psychopharmacology (Berl)       Date:  2011-02-16       Impact factor: 4.530

4.  Effects of olanzapine infusions to the ventral tegmental area on lordosis and midbrain 3alpha,5alpha-THP concentrations in rats.

Authors:  Cheryl Frye; Angela Seliga
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

5.  In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.

Authors:  Linda M Rorick-Kehn; Bryan G Johnson; Karen M Knitowski; Craig R Salhoff; Jeffrey M Witkin; Kenneth W Perry; Kelly I Griffey; Joseph P Tizzano; James A Monn; David L McKinzie; Darryle D Schoepp
Journal:  Psychopharmacology (Berl)       Date:  2007-03-24       Impact factor: 4.415

6.  In vivo pharmacological evaluations of novel olanzapine analogues in rats: a potential new avenue for the treatment of schizophrenia.

Authors:  Somayeh Jafari; Xu-Feng Huang; Jessica L Andrews; Francesca Fernandez-Enright
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.